ZYME — Zymeworks Inc. stock price, charts and financials

Latest market price

23.64

+0.10+0.42%

Overview Short InterestFilings

ZYMEQT66Zymeworks Inc.·NASDAQ

Overview Short InterestFilings

23.64+0.42%

Loading chart...

Signal & projected range

Earnings miss — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.37%$15.47 MESO+5.02%$16.74 ZBIO-1.59%$31.91 GHRS-1.92%$29.69 TSHA-0.84%$6.50 STOK-1.64%$32.17 ABCL+32.14%$9.16 VRDN-2.54%$22.99

Snapshot

Index	-	P/E	-	EPS (ttm)	-1.37	Insider Own	48.84%	Shs Outstand	73.57M	Perf Week	7.29%

Market Cap	1.73B	Forward P/E	17.99	EPS next Y	1.31	Insider Trans	0.00%	Shs Float	68.01M	Perf Month	-13.04%

Enterprise Value	1.38B	PEG	0.17	EPS next Q	-	Inst Own	-	Short Float	6.03%	Perf Quarter	-11.50%

Income	-45.48B	P/S	53.23	EPS this Y	191.71%	Inst Trans	-	Short Ratio	6.22	Perf Half Y	6.90%

Sales	82.00M	P/B	0.02	EPS next Y	4.18%	ROA	-11.37%	Short Interest	4.10M	Perf YTD	-10.60%

Book/sh	-	P/C	-	EPS next 5Y	-6.31%	ROE	-222.50%	52W High	29.87 -20.87%	Perf Year	89.69%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-11.98%	52W Low	11.56 104.52%	Perf 3Y	221.58%

Dividend Est.	-	EV/EBITDA	3.82	Sales past 3/5Y	-36.40% 22.14%	Gross Margin	86.05%	Volatility	4.87% 4.03%	Perf 5Y	-26.64%

Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	15.43%	Oper. Margin	-129985.49%	ATR (14)	1.05	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	6.32	Sales Y/Y TTM	7.89%	Profit Margin	-138685.11%	RSI (14)	49.89	Recom	2.10

Dividend Gr. 3/5Y	-	Current Ratio	6.32	EPS Q/Q	-96.67%	SMA20	0.85%	Beta	1.14	Target Price	43.40

Payout	0.00%	Debt/Eq	0.20	Sales Q/Q	-92.59%	SMA50	-1.98%	Rel Volume	0.87	Prev Close	23.54

Employees	264	LT Debt/Eq	0.06	Earnings	Nov 10	SMA200	-2.31%	Avg Volume	626.24K	Price	23.64

IPO Date	Apr 28, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-98.77% -90.12%	Net Debt/EBITDA	3.87	Volume	546,559	Change	0.42%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-07-26	Reiterated	Truist Financial	Buy	$31 → $32
Aug-07-26	Reiterated	Stifel Nicolaus	Buy	$47 → $46
Aug-07-26	Reiterated	Wells Fargo	Overweight	$37 → $40
Aug-05-26	Reiterated	HC Wainwright & Co.	Buy	$46 → $51
Jul-07-26	Reiterated	Truist Securities	Buy	$28 → $31
Jun-30-26	Reiterated	Wells Fargo	Overweight	$33 → $37
Jun-09-26	Reiterated	Truist Financial		$40 → $28
Jun-03-26	Reiterated	HC Wainwright & Co.	Buy	$26 → $46
Mar-09-26	Reiterated	Evercore ISI Group	Outperform	$48
Dec-17-25	Initiated	Truist	Buy	$40

Latest News

Aug-06-26

Aug-06-2608:12PM

Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimateszacks.com

04:05PM

Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Resultsglobenewswire.com

Aug-05-26

Aug-05-2601:49PM

HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $51Benzinga

Jul-16-26

Jul-16-2606:00AM

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026globenewswire.com

Jul-07-26

Jul-07-2608:30AM

Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $31Benzinga

Jul-01-26

Jul-01-2608:30AM

Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharmaseekingalpha.com

Jun-30-26

Jun-30-2610:24AM

Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $37Benzinga

09:55AM

Theravance Stock Down 3% After Zymeworks Announces Buyoutzacks.com

Jun-29-26

Jun-29-2603:32PM

Zymeworks Inc. (ZYME) M&A Call Transcriptseekingalpha.com

09:20AM

Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisitionbenzinga.com

06:13AM

Zymeworks strikes $929 million deal for Theravance Biopharmareuters.com

06:00AM

Zymeworks to Acquire Theravance Biopharma, Inc.globenewswire.com

Jun-15-26

Jun-15-2602:48AM

Reported Sunday, Zymeworks Presents Phase 1 Data For ZW191 ADC Showing 78.6% cORR In FRα-Positive And 47.4% In FRα-Negative Platinum-Resistant Ovarian Cancer Patients At ESMO 2026Benzinga

Company

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	82	106	76	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	5	0	0	—	—	—	—	—	—
Gross Profit	78	106	76	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	15,112	62	62	—	—	—	—	—	—
Research and Development	2,509	137	135	—	—	—	—	—	—
Other Operating Expense	-17,430	0	16	—	—	—	—	—	—
Operating Income	-114	-93	-137	—	—	—	—	—	—
Interest Expense	2	0	0	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	13	13	20	—	—	—	—	—	—
Net Income Before Taxes	-103	-80	-117	—	—	—	—	—	—
Income Taxes	-1	1	6	—	—	—	—	—	—
Consolidated Net Income	-103	-81	-123	—	—	—	—	—	—
Net Income From Continuing Operations	-103	-81	-123	—	—	—	—	—	—
Net Income	-103	-81	-123	—	—	—	—	—	—
EPS (Recurring)	-1.37	-1.08	-1.62	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-1.37	-1.08	-1.62	—	—	—	—	—	—
EPS (Diluted)	-1.37	-1.08	-1.62	—	—	—	—	—	—
EBITDA	-94	-69	-109	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	21.62	18.63	14.64	—	—	—	—	—	—
Gross Margin	95.12	100.00	100.00	—	—	—	—	—	—
Operating Margin	-139.02	-87.74	-180.26	—	—	—	—	—	—
Net Margin	-125.61	-76.42	-161.84	—	—	—	—	—	—
Shares Outstanding	75	75	76	—	—	—	—	—	—
Market Capitalization	1,773	1,975	1,113	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hollywood Mark	EVP & Chief Operating Officer	Jan 12 '26	Sale	22.67	6,120	138,762	132,913	Jan 13
Hollywood Mark	EVP & Chief Operating Officer	Jan 12 '26	Option Exercise	0.00	17,666	0	139,033	Jan 13
Moore Paul Andrew	Chief Scientific Officer	Jan 12 '26	Option Exercise	0.00	17,666	0	58,057	Jan 12
Moore Paul Andrew	Chief Scientific Officer	Jan 12 '26	Sale	22.67	9,560	216,759	48,497	Jan 12
Galbraith Kenneth	Chair & CEO	Jan 12 '26	Option Exercise	0.00	64,000	0	257,266	Jan 12
Galbraith Kenneth	Chair & CEO	Jan 12 '26	Sale	22.67	30,424	689,819	226,842	Jan 12
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 12 '26	Option Exercise	0.00	17,666	0	36,018	Jan 12
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 12 '26	Sale	22.67	9,310	211,090	26,708	Jan 12
Galbraith Kenneth	Chair & CEO	Jan 05 '26	Sale	25.10	54,343	1,363,840	158,286	Jan 05
Moore Paul Andrew	Chief Scientific Officer	Jan 05 '26	Option Exercise	0.00	37,168	0	51,212	Jan 05
Moore Paul Andrew	Chief Scientific Officer	Jan 05 '26	Sale	25.10	20,110	504,699	31,212	Jan 05
Galbraith Kenneth	Chair & CEO	Jan 05 '26	Option Exercise	0.00	114,334	0	224,952	Jan 05
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 05 '26	Option Exercise	0.00	20,000	0	28,890	Jan 05
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 05 '26	Sale	25.10	10,538	264,471	18,352	Jan 05
Galbraith Kenneth	Chair & CEO	Dec 22 '25	Option Exercise	0.00	100,000	0	180,803	Dec 22

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.